

CORPORATE OFFICE

Level 1
32 Oxford Terrace
Christchurch Central
CHRISTCHURCH 8011

Telephone: 0064 3 364 4134
Kathleen.Smithram@cdhb.health.nz

2 July 2021

9(2)(a)

RE Official Information Act request CDHB 10634

I refer to your email to the Department of Prime Minister and Cabinet dated 17 May 2021, and subsequently partially transferred through to us on 15 June 2021, requesting the following information under the Official Information Act from Canterbury DHB. Specifically:

- I request the following information relating to Managed Quarantine.

3. What treatment, if any, was given to these 'positive cases'? (since the start of the 'pandemic' up to date)

Broadly speaking, COVID-19 is an illness with a wide range of disease severity and the treatment for this varies by clinical need. Patients with either no symptoms or mild symptoms may have required no treatment. For those who required hospitalisation, treatment may have included: the anti-viral drug remdesivir, anticoagulants (blood thinners) such as enoxaparin and corticosteroids such as dexamethasone. In addition, supportive care with oxygen, intravenous fluids or ventilation support is sometimes needed.

Less than 1% of people in MIQ have tested positive for COVID-19 – the figure is 0.9%. A large proportion [70-80%] of these have been considered historic infections; these are people with infections some weeks before travel and who are no longer considered infectious.

Most travellers with acute COVID infection had minimal or mild symptoms. Very few, a hand full, mainly with non-COVID related illness, required transfer to hospital for care. None have required intensive care or therapy with oxygen and dexamethasone.

I trust that this satisfies your interest in this matter.

Please note that this response, or an edited version of this response, may be published on the Canterbury DHB website after your receipt of this response.

Yours sincerely



Tracey Maisey
Executive Director
Planning, Funding & Decision Support